Abstract X-linked nephrogenic diabetes insipidus (NDI, OMIM#304800) is caused by mutations in the arginine vasopressin (AVP, OMIM*192340) receptor type 2 (AVPR2, OMIM*300538) gene. A 20-month-old boy and his 8-yearold brother presented with polyuria, polydipsia, and failure to thrive. Both boys demonstrated partial DDAVP (1-desamino-8-D AVP or desmopressin) responses; thus, NDI diagnosis was delayed. While routine sequencing of AVPR2 showed a potential splice site variant, it was not until exome sequencing confirmed the AVPR2 splice site variant and did not reveal any more likely candidates that the patients' diagnosis was made and proper treatment was instituted. Both patients were hemi- zygous for two AVPR2 variants predicted in silico to affect AVPR2 messenger RNA (mRNA) splicing. A minigene assay revealed that the novel AVPR2 c.276A>G mutation creates a novel splice acceptor site leading to 5′ truncation of AVPR2 exon 2 in HEK293 human kidney cells. Both patients have been treated with high-dose DDAVP with a remarkable improvement of their symptoms and accelerated linear growth and weight gain. Conclusion: We present here a unique case of partial Xlinked NDI due to an AVPR2 splice site mutation; patients with diabetes insipidus of unknown etiology may harbor splice site mutations that are initially underestimated in their pathogenicity on sequence analysis.
zygous for two AVPR2 variants predicted in silico to affect AVPR2 messenger RNA (mRNA) splicing. A minigene assay revealed that the novel AVPR2 c.276A>G mutation creates a novel splice acceptor site leading to 5′ truncation of AVPR2 exon 2 in HEK293 human kidney cells. Both patients have been treated with high-dose DDAVP with a remarkable improvement of their symptoms and accelerated linear growth and weight gain.
Conclusion: We present here a unique case of partial Xlinked NDI due to an AVPR2 splice site mutation; patients with diabetes insipidus of unknown etiology may harbor splice site mutations that are initially underestimated in their pathogenicity on sequence analysis.
What is Known:
• X-linked nephrogenic diabetes insipidus is caused by AVPR2 mutations, and disease severity can vary depending on the functional effect of the mutation.
What is New:
• We demonstrate here that a splice site mutation in AVPR2 leads to partial X-linked NDI in two brothers.
• Treatment with high-dose DDAVP led to improvement of polyuria and polydipsia, weight gain, and growth.
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Introduction
Diabetes insipidus (DI) is characterized by complete or partial loss of arginine vasopressin (AVP) function leading to polyuria, polydipsia, and hypernatremia. This is due to either posterior pituitary defects leading to low, absent, or erroneous AVP production (central DI, OMIM#125700), or due to a disruption in the signaling machinery mediating AVP effects in the kidney (nephrogenic DI (NDI)).
AVP receptor type 2 (AVPR2) is a G protein-coupled receptor [7] that acts as the primary mediator of the water-conserving action of AVP in the kidney. Activation of AVPR2 by AVP binding ultimately leads to the translocation of aquaporin 2 (AQP2, OMIM*107777) to the apical surface of the principal cells in the kidney collecting duct; this occurs via activation of the cAMP-dependent protein kinase (PKA) pathway, thereby increasing water reabsorption and urine osmolality [13] .
Mutations in AVPR2 lead to X-linked NDI. The AVPR2 gene resides on chromosome Xq28 and consists of three exons [7] . More than 220 AVPR2 variants have been shown to cause X-linked NDI, and there is considerable phenotypic variability in the response to fluid deprivation and DDAVP administration [1, 13] . Missense mutations can lead to (partially) preserved receptor expression and function and hence a milder DI phenotype [11] . Three AVPR2 splice site mutations have been described in patients with X-linked NDI [8, 13] .
Here, we present two brothers with an identical, novel splice site mutation in AVPR2 leading to partial X-linked NDI. Exome sequencing previously led to the identification of pathogenic variants [2] ; in our case, the defects were identified by Sanger sequencing and subsequently confirmed by exome sequencing after multiple attempts to identify the nature of disease in these two siblings had failed previously. We report the patients' clinical features as well as functional analysis of the effect of the mutation on messenger RNA (mRNA) splicing.
Results
A 20-month-old boy (II-4, Fig. 1a ) presented with failure to thrive, nausea, recurrent fevers, polyuria, and polydipsia. He was enrolled in the NIH Undiagnosed Diseases Program [4, 5] as well as National Human Genome Research Institute (NHGRI) clinical protocol 76-HG-0238, BDiagnosis and Treatment of Patients with Inborn Errors of Metabolism and Other Genetic Disorders^; his parents gave written informed consent. The boy was born at 39 weeks after a pregnancy that was complicated by polyhydramnios. Laboratory evaluation showed hypernatremia (146 mEq/L, Table 1 ) with elevated serum osmolality (313 mOsm/kg) and inappropriately low urine osmolality (234 mOsm/kg, Table 1 ). AVP levels were elevated (20, range 0.7-3.8 pg/mL). Pituitary MRI showed the absence of a posterior pituitary bright spot (Fig. 1b) ; while this is a typical radiological finding in central DI, the posterior pituitary bright spot is also often absent in NDI [3] . A water deprivation test failed to adequately increase urine osmolality (Table 1) . However, DDAVP administration (1 μg s.c.) increased urine osmolality to 511 mOsm/kg, which is consistent with partial NDI.
The patient's older brother (II-1, then 8 years old, Fig. 1a ), also presented with polyuria, polydipsia, and failure to thrive and was subsequently diagnosed with DI (Table 1) , while the two parents, a sister, and a brother do not have DI (Fig. 1a) .
Initial Sanger sequencing reported no protein-coding variants in AVPR2 or AQP2, with mention made of a possible splicing effect of a synonymous change, c.276A>G (variant 1). We performed exome sequencing and found the same variant and a second variant in AVPR2, c.26-6T>G (rs56689668; variant 2), both predicted in silico to affect mRNA splicing, and no other more likely candidates. The two affected children were hemizygous for these variants; the patients' mother (I-2) and sister (II-2) were heterozygous for these variants (Fig. 1a) .
The novel AVPR2 c.276A>G variant was predicted in silico to create a novel splice acceptor site at c.277 that could lead to skipping of the first 251 bases of exon 2 and create a 5′ truncated exon 2. The second variant was identified in the 1000 Genomes Project with an allele frequency of 0.003 [6] and could reduce the efficiency of the natural splice acceptor site of intron 1 (c.26).
AVPR2 mRNA species in peripheral blood lymphocytes of the affected patient, his mother, and three healthy controls were tested by reverse transcription PCR (RT-PCR) for the predicted effect of variant 1. The forward primer binds within the predicted truncated region of AVPR2 exon 2. RT-PCR products were present in all samples at the sizes expected for exon 2 without truncation (Fig. 2a) . Sequencing of the RT-PCR products confirmed the presence of AVPR2 exon 2 in both the proband and the mother; the patient's mRNA contained only the c.276A>G mutation whereas the mother's mRNA contained both the mutation and the wild-type (Fig. 2b) , so we did not find evidence of alternative splicing in the lymphocyte mRNA of the patient. Alternative splicing due to pathogenic splice site variants may be regulated in a tissuespecific fashion [12] , so that the splicing effect of the c.276A>G variant may differ in lymphocytes and kidney tubules; furthermore, lymphocytes are not a primary AVP target tissue and may not physiologically express relevant amounts of AVPR2. Both variants were functionally studied in a minigene assay. Exon 2 of wild-type AVPR2 and exon 2 containing one or both variants together with the flanking intronic sequences were cloned into the pSPL3 vector. After transfection into HEK293 human kidney cells, mRNA synthesis from the plasmids using the cells' own transcription and splicing machinery led to mRNA products containing exon 2 of AVPR2 flanked by two exons from the pSPL3 vector (Fig. 2d) .
Variant 1 leads to an approximately 900 bp product, while the wild-type product was approximately 1200 bp long (Fig. 2c) . In addition, variant 1 also causes a second faint band at 1200 bp, indicating a small amount of correctly spliced product; these results suggest that the variant leads to <15 % of correctly spliced product in this semi-quantitative experimental setting by density measurements. The bands from the wild-type and variant 1 were gel purified, subcloned into pGEM-TEasy, and sequenced. Sequencing confirmed that the wild-type band contained the full-length exon 2 including the non-mutated c.276A, while variant 1 consisted of a 5′ truncated exon 2 lacking its first 251 bases (Δc.26-276, Fig. 2d ). This deletion is followed by a frameshift and subsequent stop codon after 99 amino acids in the new reading frame (p.Ala9Glyfs*99, Fig. 2d) . The c.26-6T>G variant did not have an independent effect in this assay, and the construct containing both variants led to the same product as that seen with the c.276A>G mutation alone (Fig. 2c) .
Both the patient and his affected brother were assessed at our center at ages 1 year and 8 months (II-4) and 8 years (II-1); subsequently, fluid deprivation tests were performed. Both patients had received ibuprofen and hydrochlorothiazide since age 2, which did not have a significant effect on polyuria and polydipsia; patient II-1 continued to have a fluid intake of more than 3 L every day, with frequent urination (every 1-2 h) and nocturia (at least three to four times each night). They were followed up at ages 2 years and 2 months (II-4) and 9 years (II-2), when intranasal DDAVP therapy was initiated following the establishment of the diagnosis of X-linked NDI due to the AVPR2 splice site mutation. Lastly, both patients were evaluated at ages 3 years and 7 months (II-4) and 10 years (II-1), where an improvement of intranasal DDAVP on DI symptoms as well as growth and weight gain were noted (Fig. 1c, d ). Due to the high dosage of DDAVP required, both patients receive nasal spray (0.90 mg/day II-1 and 0.45 mg/day II-4) in the highly concentrated formulation typically used to treat Von Willebrand disease (Stimate).
Discussion
We detected a novel AVPR2 splice site mutation as a cause of partial X-linked NDI in two male siblings. The novel AVPR2 c. 276A>G mutation causes alternative splicing leading to the 5′ truncation of exon 2, as shown in a minigene assay. c.276A>G directly creates a novel 3′ splice acceptor site for intron 1, which is more similar to the consensus 3′ splice site than the authentic 3′ splice site for intron 1, suggesting the preferential usage of the novel splice site by the splicing machinery (as predicted in silico by multiple methods using the Alamut Splicing Prediction Module, Interactive Biosoftware). This truncation causes a frameshift followed by a premature stop codon that would presumably target the mRNA for nonsense-mediated decay and lead to absence of AVPR2 protein; this is likely to underlie the pathogenic mechanism for NDI in these patients.
AVPR2 mutations causing NDI can vary in their functional severity; clinical symptoms and the response to DDAVP can be diverse. Three cases of X-linked NDI caused by splice site mutations [13] have been described, but to our knowledge, no AVPR2 splice site mutation has been functionally studied. Although there were phenotypic differences in disease severity of those splice site mutations, a partial DDAVP response has not been described [8, 13] . Fig. 2 Analysis of splice site mutations in AVPR2. a RT-PCR was performed on peripheral blood lymphocyte cDNA from three controls (C1-C3), the affected patient (II-4), and his mother (I-2), with primers covering most of exon 2 and both sides of AVPR2 c. 276A>G. We did not find evidence of alternative splicing in the affected patient's lymphocytes, possibly due to tissue-specific regulation of alternative splicing (cf Results section). A control PCR on the same samples was performed using primers for GAPDH. b Sequencing of the AVPR2 exon 2 RT-PCR products of the patient and his mother where the locus of the mutation is highlighted (arrows). c Minigene assay. cDNA from untransfected HEK293, empty vector-transfected HEK293 (EV), the AVPR2 wt and three variants in pSPL3, and negative controls (reverse transcription negative controls without reverse transcriptase or without RNA and RT-PCR negative control without cDNA). The arrows point to the mutationspecific bands that were sequenced. d Locations and corresponding sequencing results in the wt (top) and AVPR2 c.276A>G mutant cDNA (bottom) obtained from the minigene assay. Shown is the 5′pSPL3-AVPR2 exon 2 junction, where the wt contains the start of exon 2 as well as the non-mutated c.276, whereas the mutant starts at AVPR2 c.277. The 3′AVPR2 exon 2-pSPL3 junction is identical in both cDNA products. The locations of the mutation (star) and stop codon (circle) are marked in the mutant diagram, and the corresponding cDNA sequences as well as translated amino acid sequences for the actual and hypothetical (mutant) product are shown. Product sizes after RT-PCR using the SD6 and SA2 primers are stated AVPR2 nonsense mutations generally lead to nonsensemediated decay and hence complete absence of the receptor [14] . Although partial NDI phenotypes have been described, these are mostly found in patients with missense mutations in which the AVPR2 receptor is present at the cell membrane [11] . However, the newly created splice acceptor site in our case may not be sufficiently strong to abolish all correct splicing of AVPR2. The natural splice acceptor site of intron 1 could retain some of its function, which may allow the production of a small amount of correctly spliced AVPR2 mRNA, as described in other diseases caused by splice site mutations [10] . This is confirmed by the minigene assay, where a small amount of wild-type product is also present in the c.276A>G mutation. It is also consistent with the clinical phenotype of partial NDI with a response to unusually high-dose DDAVP. To our knowledge, this is the first clinical and functional description of an AVPR2 splice site mutation leading to a partial NDI phenotype.
Standard management of X-linked NDI in children includes hydrochlorothiazide and indomethacin [14] . These treatments, however, only partially improve symptoms, generally decreasing urine volume by about 30-70 % [9] . Partial NDI can be treated with high doses of DDAVP; due to the AVP resistant nature of partial NDI, DDAVP plasma concentrations are supraphysiologic in contrast to dosages used in hypophyseal DI. To reach these plasma concentrations, conventional subcutaneous administration would require multiple injections per day and oral administration a large volume of tablets [3] . Consequently, our patients are treated with nasal DDAVP, which is available at a higher dosage.
In conclusion, patients with DI of unknown etiology can harbor splice site mutations whose pathogenicity may initially be underestimated on routine sequence analysis. The predicted amino acid sequence was not affected by this novel mutation, and functional studies were required to demonstrate an effect on mRNA splicing. Functional assays testing potential splice site variations are not routinely performed; in our case, the minigene assay was only performed after exome sequencing did not reveal any more likely candidates. Variants potentially generating pathogenic splicing effects should be considered in cases of partial DI where no coding mutation is identified, and their effects should be verified in functional assays. Furthermore, AVPR2 splice site mutations may lead to a partial NDI phenotype that can be confusing in terms of its pathophysiology; this form of NDI can be managed by high-dose DDAVP administration.
